Effect of Doxazosin Gastrointestinal Therapeutic System 4 mg vs Tamsulosin 0.2 mg on Nocturia in Chinese Men With Lower Urinary Tract Symptoms: A Prospective, Multicenter, Randomized, Open, Parallel Study

Objective To compare the efficacy of the doxazosin gastrointestinal therapeutic system (doxazosin-GITS) 4 mg and tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). Methods Data were analyzed from a prospective, multicenter, randomized, open, parallel study of Chinese men aged 50-84 years with LUTS/BPH. Two hundred patients were randomized to receive daily treatment with 4 mg doxazosin-GITS (n = 100) or 0.2 mg tamsulosin (n = 100) for 8 weeks. Nocturia was assessed by question 7 of the International Prostate Symptom Score (IPSS-question 7) and a frequency–volume chart (FVC) at weeks 4 and 8. Self-reported quality of sleep and quality of life by the last question of the IPSS questionnaire were also evaluated. Results A total of 189 patients (94 receiving doxazosin-GITS, 95 tamsulosin) completed the study. The reduction from baseline in mean nocturia was greater with doxazosin-GITS than tamsulosin by the FVC (1.7 vs 1.3 at week 4; 2.1 vs 1.7 at week 8, both P = .001) and by the IPSS-question 7 (1.5 vs 1.1 at 4 weeks, P = .001; 2.0 vs 1.6 at 8 weeks, P P = .020; 81.9% vs 67.4% at 8 weeks, P = .022), and quality of life was better with doxazosin-GITS (2.5 vs 2.8 at 4 weeks, P = .001; 2.1 vs 2.5 at 8 weeks, P Conclusion In Chinese patients with LUTS/BPH, doxazosin-GITS is slightly better than tamsulosin in reducing the frequency of nocturia.